North Carolina

Psychedelic trials in North Carolina

21 registered trials has a study site in North Carolina, and 1 is recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSDNCT06608277 · Northwestern University	Recruiting	Phase 2	ketamine	3

Facilities

Where the research happens in North Carolina

Facility	City	Trials
Wake Forest Baptist Medical Center	Winston-Salem	2
Womack Army Medical Center	Fort Bragg	1
Asheville VA Medical Center, Asheville, NC	Asheville	1
Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC	Salisbury	1
Monroe Biomedical Research	Monroe	1
Atrium Health Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem	1
UNC Chapel Hill Medical Center	Chapel Hill	1
Naval Medical Center Camp Lejeune	Marine Corps Base Camp Lejeune	1
Clinical Trials of America	Hickory	1
University of North Carolina	Chapel Hill	1
The Pearl Institute	Waynesville	1
Clinical Site 111	Hickory	1
Clinical Site 143	Raleigh	1
University North Carolina at Chapel Hill	Chapel Hill	1
Research Site, Charlotte	Charlotte	1
Duke Early Phase Clinical Research	Durham	1
Wake Forest University Health Sciences	Winston-Salem	1
Pearl Psychedelic Institute	Waynesville	1
Carolina Center for Neurostimulation	Chapel Hill	1

Stay told

When a trial opens in North Carolina

All trials

Every trial with a North Carolina site

Trial	Status	Phase	Substance	Sites
Ketamine, SGB and Combination Treatment for TBI-associated Headache or PTSDNCT06608277 · Northwestern University	Recruiting	Phase 2	ketamine	3
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL Limited	Active, not recruiting	Phase 3	psilocybin	45
Opioid-Free Pain Control Regimen Following Robotic Radical ProstatectomyNCT05597878 · Wake Forest University Health Sciences	Terminated	Phase 2 / Phase 3	ketamine	1
Psilocybin-Assisted Therapy in Treatment-Resistant DepressionNCT06303739 · University of North Carolina, Chapel Hill	Active, not recruiting	Phase 3	psilocybin	1
Initiating Ketamine in Acutely Suicidal Patients in the Emergency DepartmentNCT04260607 · Naval Medical Center Camp Lejeune	Terminated	Phase 3	ketamine	1
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	90
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	61
MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First RespondersNCT05455996 · Nautilus Sanctuary	Not yet recruiting	Phase 2	mdma	3
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO StudyNCT04103892 · Clexio Biosciences Ltd.	Completed	Phase 2	ketamine	46
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	51
Sequential Therapy for the Treatment of Severe Bipolar Depression.NCT02974010 · NeuroRx, Inc.	Completed	Phase 2	ketamine	4
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive DisorderNCT01957410 · Janssen Research & Development, LLC	Terminated	Phase 2	ketamine	1
Phase 1 Evaluation of (2R,6R)-HydroxynorketamineNCT04711005 · National Institute of Mental Health (NIMH)	Completed	Phase 1	ketamine	1
The Effects of Sedatives on Tobacco Use Disorder Version 2NCT05505630 · Wake Forest University Health Sciences	Completed	Early Phase 1	ketamine	1
Effect of Ketamine and Etomidate During RSI on Long Term OutcomesNCT06179485 · Vanderbilt University Medical Center	Enrolling by invitation	N/A	ketamine	6
A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSDNCT04438512 · Resilient Pharmaceuticals	No longer available	N/A	mdma	2
Brain Network Dynamics of Depression During Esketamine TreatmentNCT06012916 · University of North Carolina, Chapel Hill	Completed	N/A	ketamine	1

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere